Evolent Health (EVH) reported $444.33 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 31.3%. EPS of -$0.10 for the same period compares to $0.30 a year ago.
The reported revenue represents a surprise of -2.86% over the Zacks Consensus Estimate of $457.4 million. With the consensus EPS estimate being $0.09, the EPS surprise was -211.11%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Evolent Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Average PMPM Fees / Revenue per Case - Performance Suite: $13.76 versus $14.21 estimated by three analysts on average.
- Average PMPM Fees / Revenue per Case - Specialty Technology and Services Suite: $0.35 versus $0.36 estimated by three analysts on average.
- Average PMPM Fees / Revenue per Case - Administrative Services: $15.13 versus the three-analyst average estimate of $15.82.
- Average Lives on Platform / Cases - Cases: 13 thousand versus the three-analyst average estimate of 14.39 thousand.
- Average Lives on Platform / Cases - Performance Suite: 6.49 million compared to the 6.48 million average estimate based on three analysts.
- Average Lives on Platform / Cases - Specialty Technology and Services Suite: 77.02 million versus 77.71 million estimated by three analysts on average.
- Average Lives on Platform / Cases - Administrative Services: 1.23 million compared to the 1.22 million average estimate based on three analysts.
- Average PMPM Fees / Revenue per Case - Cases: $2,969.00 versus the three-analyst average estimate of $3,008.56.
View all Key Company Metrics for Evolent Health here>>>
Shares of Evolent Health have returned -16.7% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Evolent Health, Inc (EVH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
